A Phase 2 Study of Anvumetostat in Participants With MTAP-deleted Advanced NSCLC (MTAPESTRY 201) (NCT06593522)
A Phase 2 Study Evaluating the Efficacy, Safety, Tolerability, and Pharmacokinetics of Anvumetostat in Subjects With Methylthioadenosine Phosphorylase (MTAP)-Deleted Previously Treated Advanced Non-Small Cell Lung Cancer (NSCLC)
🩺 Plain-English Summary (8th-Grade Level)
The main objective of the study is to characterize safety and efficacy of 2 dose levels of anvumetostat by investigator, and to evaluate anvumetostat monotherapy efficacy by Blinded Independent Central Review (BICR).
Who can join: Review the eligibility criteria below.
Location: City of Hope National Medical Center — Duarte, California
Age range: 18 Years to 99 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (91 Sites)
Showing the first 25 of 91 sites.
- City of Hope National Medical Center — Duarte, California
- City of Hope Orange County Lennar Foundation Cancer Center — Duarte, California
- Cedars-Sinai Medical Center — Los Angeles, California
- Valkyrie Clinical Trials — Los Angeles, California
- University of California Los Angeles — Los Angeles, California
- Rocky Mountain Cancer Centers — Denver, Colorado
- Eastern Connecticut Hematology and Oncology Associates — Norwich, Connecticut
- Hartford HealthCare Cancer Institute - Manchester — Plainville, Connecticut
- Medstar Georgetown University Hospital — Washington D.C., District of Columbia
- Our Lady of the Lake Cancer Institute — Baton Rouge, Louisiana
- Trinity Health Saint Joseph Mercy Ann Arbor — Ann Arbor, Michigan
- Cancer and Hematology Centers of Western Michigan — Grand Rapids, Michigan
- Sarah Cannon Research Institute Oncology Partners — Nashville, Tennessee
- United States Oncology Regulatory Affairs Corporate Office — Nashville, Tennessee
- Texas Oncology Central/South Texas — Austin, Texas
- Sarah Cannon Research Institute — Dallas, Texas
- Texas Oncology - Dallas Fort Worth — Dallas, Texas
- US Oncology Research Investigational Products Center — Irving, Texas
- Texas Oncology Northeast Texas — Tyler, Texas
- Virginia Cancer Specialists PC — Fairfax, Virginia
- GenesisCare -North Shore Oncology — St Leonards, New South Wales
- Calvary Mater Newcastle Hospital — Waratah, New South Wales
- Mater Hospital Brisbane — South Brisbane, Queensland
- Cancer Research South Australia — Adelaide, South Australia
- Núcleo de Oncologia da Bahia — Salvador, Estado de Bahia
📞 Contact the Study Coordinator
Phone: (800) 826-4673
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
Explore by condition: All MTAP-deleted NSCLC clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.